Cranoc en es it fr

Cranoc Brand names, Cranoc Analogs

Cranoc Brand Names Mixture

  • No information avaliable

Cranoc Chemical_Formula


Cranoc RX_link

Cranoc fda sheet

Cranoc FDA

Cranoc msds (material safety sheet)

Cranoc Synthesis Reference

F. G. Kathawala, U.S. Pat. 4,739,073 (1988)

Cranoc Molecular Weight

411.466 g/mol

Cranoc Melting Point


Cranoc H2O Solubility

0.46 mg/L

Cranoc State


Cranoc LogP


Cranoc Dosage Forms

Capsules; Tablets (extended-release)

Cranoc Indication

For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia

Cranoc Pharmacology

Fluvastatin, the first synthetically-prepared HMG-CoA reductase inhibitor, is used as an antilipemic to lower cholesterol and triglyceride levels associated with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb) and to slow the progression of coronary atherosclerosis in patients with coronary artery disease. Although similar to lovastatin, simvastatin, and pravastatin, Fluvastatin has a shorter half-life, no active metabolites, extensive protein binding, and minimal CSF penetration.

Cranoc Absorption

24% (range 9%-50%).

Cranoc side effects and Toxicity

Variety of GI complaints and an increase in transaminase values (i.e., SGOT and SGPT).

Cranoc Patient Information


Patients should be advised to report promptly unexplained muscle pain, tenderness or
weakness, particularly if accompanied by malaise or fever.

Women should be informed that if they become pregnant while receiving Lescol or Lescol
XL the drug should be discontinued immediately to avoid possible harmful effects on a
developing fetus from a relative deficit of cholesterol and biological products derived
from cholesterol. In addition, Lescol or Lescol XL should not be taken during nursing.

Cranoc Organisms Affected

Humans and other mammals